Doxazosin

證據等級: L5

預測適應症: 2 個

Doxazosin: From Hypertension to Migraine Disorder

One-Sentence Summary

Doxazosin is a selective alpha-1 adrenergic receptor blocker commonly used to treat hypertension and benign prostatic hyperplasia (BPH). The TxGNN model predicts it may be effective for Migraine Disorder, though only 0 clinical trials and 1 publication currently support this direction. A closely related prediction — Migraine with Brainstem Aura — also emerged at nearly identical confidence (Rank 2, 99.19%), likely reflecting knowledge graph node adjacency rather than independent mechanistic evidence.

Quick Overview

Item	Content
Original Indication	Hypertension; Benign Prostatic Hyperplasia (BPH)
Predicted New Indication	Migraine Disorder
TxGNN Prediction Score	99.20%
Evidence Level	L4
Canada Market Status	Not Marketed
Number of DINs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data was not available in this evidence pack. Based on established pharmacology, doxazosin is a selective alpha-1 adrenergic receptor antagonist: it blocks post-synaptic alpha-1 receptors in vascular smooth muscle, causing vasodilation and reducing peripheral resistance. Importantly, alpha-1 receptors are also expressed on cerebral arterial smooth muscle, which provides the theoretical basis for the TxGNN prediction — alpha-1 blockade could attenuate cerebrovascular constriction and theoretically modulate the vascular component of migraine attacks.

Migraine pathophysiology involves the trigeminovascular system and dynamic regulation of cerebrovascular tone. The rationale embedded in the evidence pack articulates this pathway: α1 receptor blockade → cerebral vasodilation → dampening of vasoconstrictive triggers in migraine. This mechanistic chain is biologically plausible at a conceptual level, and the single 1997 clinical observation (10 patients) noted improvement in 9 of 10 cases treated with alpha-1 blockers.

However, the overall mechanistic confidence is rated Low, and several counterarguments must be weighed. First-line migraine prophylactics are beta-blockers (propranolol), CGRP antagonists, and anticonvulsants — none of which act via alpha-1 blockade. Doxazosin’s blood pressure–lowering effect may also trigger compensatory sympathetic rebound and reflex vasodilation, potentially worsening headache rather than alleviating it. The second-ranked prediction (migraine with brainstem aura) carries Very Low confidence and is assessed as a pure computational adjacency inference, with no independent mechanistic support specific to that subtype.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
9074296	1997	Narrative Review / Commentary	Headache	Single-author report from a general neurology practice: 10 migraine patients treated with terazosin or doxazosin. Migraine frequency or severity decreased in 9 of 10 patients; however, 5 discontinued due to side effects. No serious adverse reactions reported. Study is uncontrolled, n=10, and nearly 30 years old — findings are hypothesis-generating only and require formal prospective validation.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The entire evidence base consists of a single 1997 narrative commentary (n=10, uncontrolled) and a TxGNN knowledge graph prediction. There are no registered clinical trials, no controlled studies, and the mechanistic link is assessed as weak-to-moderate at best. Additionally, doxazosin is not marketed in Canada, and critical safety data — including key warnings and contraindications — are currently unavailable.

To proceed, the following is needed:

Retrieve the official product monograph or package insert (e.g., from Health Canada or a marketed jurisdiction) to establish key warnings, contraindications, and drug interaction profile
Obtain full MOA data from DrugBank to formally characterise the mechanistic rationale and assess its applicability to migraine neurobiology
Conduct a systematic literature search across MEDLINE, Embase, and Cochrane to identify any additional preclinical, observational, or open-label studies that may have emerged since 1997
Evaluate whether a small, prospective proof-of-concept study is warranted given the safety/tolerability signals (50% discontinuation rate in the single available report)
Clarify Canada regulatory pathway (Health Canada NDS/SNDS or Section 56 exemption) only if preclinical and safety evidence sufficiently strengthens the case
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.